U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C28H38NO4.Br
Molecular Weight 532.51
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUTROPIUM BROMIDE

SMILES

[Br-].CCCCOC1=CC=C(C[N@+]2(C)[C@H]3CC[C@@H]2C[C@@H](C3)OC(=O)[C@H](CO)C4=CC=CC=C4)C=C1

InChI

InChIKey=JABDOYKGZCPHPX-XSCYYCMVSA-M
InChI=1S/C28H38NO4.BrH/c1-3-4-16-32-25-14-10-21(11-15-25)19-29(2)23-12-13-24(29)18-26(17-23)33-28(31)27(20-30)22-8-6-5-7-9-22;/h5-11,14-15,23-24,26-27,30H,3-4,12-13,16-20H2,1-2H3;1H/q+1;/p-1/t23-,24+,26+,27-,29?;/m1./s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.mims.com/malaysia/drug/info/coliopan and http://www.genome.jp/dbget-bin/www_bget?D01491

Butropium Bromide is an anticholinergic and an antispasmodic. It is a Muscarinic receptor antagonist. The drug is used for remission of spasmodic pain in the following diseases: gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia). It is marketed in Japan under the brand name Coliopan.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
Coliopan

Approved Use

Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia)

Launch Date

1974
Palliative
Approved
8583
Coliopan

Approved Use

Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia)

Launch Date

1974
Palliative
Approved
8583
Coliopan

Approved Use

Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia)

Launch Date

1974
Doses

Doses

DosePopulationAdverse events​
10 mg 3 times / day multiple, oral
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/210295/V_36481_20191101_110605_D4.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: unknown
Food Status: UNKNOWN
Sources:
https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/210295/V_36481_20191101_110605_D4.pdf
Sources:
https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/210295/V_36481_20191101_110605_D4.pdf
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
Other AEs: Palpitation, Increased thirst...
Other AEs:
Palpitation
Increased thirst
Urination difficulty (1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
AEs

AEs

AESignificanceDosePopulation
Increased thirst
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
Palpitation
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
Urination difficulty 1 pt
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
PubMed

PubMed

TitleDatePubMed
Endoscopic manometry of the sphincter of Oddi in dogs. Pharmacological effects of anticholinergic and selective antimuscarinic agents.
1987-05
Sensation of aural fullness and its treatment with an autonomic nerve blocking agent.
1987
Effect of glucagon on gastric motility examined by the acetaminophen absorption method and the endoscopic procedure.
1985
Patents

Patents

US20080220441
4
US20120231047
2
US6024976
5

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be administered intramuscularly http://www.ncbi.nlm.nih.gov/pubmed/7182948
Capsules 5 mg:The usual adult dosage for oral use is 6 capsules (30 mg ofbutropium bromide) daily in three divided doses. Tablets 10 mg:The usual adult dosage for oral use is 3 tablets (30 mg ofbutropium bromide) daily in three divided doses. Granules 2 %:The usual adult dosage for oral use is 1.5 g (30 mg ofbutropium bromide) daily in three divided doses.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
COLIOPAN
Preferred Name English
BUTROPIUM BROMIDE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
8-(P-BUTOXYBENZYL)-3.ALPHA.-HYDROXY-1.ALPHA.H,5.ALPHA.H-TROPANIUM BROMIDE (-)-TROPATE
Common Name English
8-AZONIABICYCLO(3.2.1)OCTANE, 8-((4-BUTOXYPHENYL)METHYL)-3-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-8-METHYL-, BROMIDE, (3(S)-ENDO)-
Common Name English
BUTROPIUM BROMIDE [MART.]
Common Name English
BUTROPIUM BROMIDE [JAN]
Common Name English
BUTROPIUM BROMIDE [MI]
Common Name English
Butropium bromide [WHO-DD]
Common Name English
butropium bromide [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
Code System Code Type Description
SMS_ID
100000081568
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
EVMPD
SUB06037MIG
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
INN
3498
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
ChEMBL
CHEMBL2110820
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
EPA CompTox
DTXSID1022716
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
CHEBI
31327
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
FDA UNII
R3K4503MV7
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
ECHA (EC/EINECS)
249-375-4
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
MERCK INDEX
m2806
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C81548
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
MESH
C006846
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
CAS
29025-14-7
Created by admin on Wed Apr 02 07:43:27 GMT 2025 , Edited by admin on Wed Apr 02 07:43:27 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of BUTROPIUM
SUBSTANCE RECORD
Structure of BUTROPIUM BROMIDE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966